Corporate VCs have played a crucial role in financing life sciences companies for decades, but have you ever wondered what, if anything, makes them different from institutional venture capital funds? Join us for this webinar as we talk to a panel of investors at industry-leading CVC funds to learn more about their strategies, investment criteria, and how they measure success.
A common practice across universities that hold equity in a company that IPOs is to sell all of its shares as soon as the lock up expires. But do the best returns necessarily come from selling all your stock immediately? When is the right time to sell stock in a therapeutics company?
Over the past several years, there’s been a proliferation of universities launching internally-driven accelerator programs, with the goal of providing inventors of early stage technologies an opportunity to develop their startup idea within an academic setting. The core concept behind a university accelerator is to offer funding, mentorship, and other resources to startups sometimes too nascent to attract seasoned talent and institutional funding. But such accelerators require large amounts of capital and an experienced team to administer programming, evaluate startups ideas, allocate funding, and provide company-building services amongst other tasks.
Columbia Technology Ventures (CTV) and venture investors Osage University Partners (OUP) invite you to join a seminar on the following topic: “Understanding the real economics of university startup formation.”
OUP principal John Lee will take you step-by-step through the life of a company, illustrating the different types equity, the pros and cons of each equity type depending on different company outcomes, and the economic effect this has on founders’ shares. Data will be presented to support the conversation around founders’ equity, the right allocation between faculty vs. post docs vs. grad students, and how much equity one needs to give away to attract and keep your top talent.
This workshop will focus on teaching you how to help investigators focus their technology disclosures, funding pitches, and other presentations on the three key factors crucial to gaining interest and commitment: commercial potential, technical merit and investigator willingness to assist.